Bausch & Lomb (BLCO) Net Income towards Common Stockholders (2021 - 2026)
Bausch & Lomb (BLCO) posted Net Income towards Common Stockholders of -$70.0 million for Q1 2026, down 20.69% on a QoQ basis from -$58.0 million in Q4 2025, and up 66.82% year-over-year from -$42.0 million in Q1 2025.
Bausch & Lomb (BLCO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Bausch & Lomb's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 66.82% year-over-year to -$70.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$211.0 million (up 40.23% YoY) and the FY2025 annual result came in at -$352.0 million, down 15.41% from the prior year.
- Net Income towards Common Stockholders was -$70.0 million for Q1 2026 at Bausch & Lomb, down from -$58.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $23.0 million in Q1 2022 and bottomed at -$211.0 million in Q1 2025.
- A 5-year average of -$60.0 million and a median of -$54.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 110.0% — and 2025, when it tumbled 2800.0%.
- Bausch & Lomb's Net Income towards Common Stockholders stood at -$15.0 million in 2022, then plunged by 240.0% to -$51.0 million in 2023, then jumped by 96.08% to -$2.0 million in 2024, then tumbled by 2800.0% to -$58.0 million in 2025, then retreated by 20.69% to -$70.0 million in 2026.
- Business Quant data shows BLCO's Net Income towards Common Stockholders at -$70.0 million in Q1 2026, -$58.0 million in Q4 2025, and -$25.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.93 Bn | 121.71 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.94 Bn | 44.13 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 33.13 Bn | 31.47 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.87 Bn | 30.63 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.48 Bn | 27.82 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.28 Bn | 22.84 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 14.11 Bn | 13.55 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.80 Bn | 13.66 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.06 Bn | 11.00 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Bausch & Lomb | 5.84 Bn | 5.56 Bn | 973.00 Mn | -70.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.00 Mn |
| Dec 31, 2025 | -58.00 Mn |
| Sep 30, 2025 | -25.00 Mn |
| Jun 30, 2025 | -58.00 Mn |
| Mar 31, 2025 | -211.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | -148.00 Mn |
| Mar 31, 2024 | -163.00 Mn |
| Dec 31, 2023 | -51.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -29.00 Mn |
| Mar 31, 2023 | -88.00 Mn |
| Sep 30, 2022 | -15.00 Mn |
| Jun 30, 2022 | 7.00 Mn |
| Mar 31, 2022 | 23.00 Mn |
| Dec 31, 2021 | 54.00 Mn |
| Sep 30, 2021 | 63.00 Mn |
| Jun 30, 2021 | 46.00 Mn |
| Mar 31, 2021 | 30.00 Mn |